Inflammation needs an ending. After an injury or infection, the immune system must move from defending tissue to repairing it. That transition is an active biological process, and a UCL study has identified one of the chemical pathways that helps regulate it in people.
The researchers found that protecting certain fat-derived signaling molecules changed the behavior of immune cells during a controlled inflammatory reaction. Pain also resolved more quickly. Published in Nature Communications on January 16, 2026, the work offers a possible route toward treatments for persistent inflammation. It did not demonstrate slower aging, better long-term health or increased lifespan.
Creating a controlled inflammatory response
Healthy male volunteers received small injections of ultraviolet-killed E. coli bacteria into their forearms. The bacteria could not multiply, but their presence triggered a temporary local reaction. Researchers sampled blood and fluid from suction blisters to follow the response.
UCL describes two treatment comparisons, each involving 24 volunteers: 12 treated and 12 untreated. One group received the experimental drug GSK2256294 two hours before inflammation was induced; another received it four hours afterward. The second approach asked whether the pathway could be influenced after symptoms had begun.
The original paper specifies that treatment allocation was not randomized and that untreated participants received no placebo. That is an important qualification to the university announcement, which uses the word placebo when describing the groups.
Fat-derived messages that help regulate immunity
Epoxy-oxylipins are small signaling molecules made from fatty acids. Rather than serving mainly as fuel or structural material, they carry messages that can alter what nearby cells do. Enzymes in the cytochrome P450 family help produce them.
Another enzyme, soluble epoxide hydrolase, or sEH, converts these molecules into related compounds. GSK2256294 inhibits that enzyme. The idea was to preserve the original signals for longer and test how the inflammatory response changed.
The treatment increased two particular epoxy-oxylipins, 12,13-EpOME and 14,15-EET. The findings do not mean all fat-derived molecules are anti-inflammatory, or that eating more of a particular fat would reproduce the drug’s effects.
What changed, and what did not
The clearest immune finding concerned intermediate monocytes, a subset of white blood cells that can become more abundant in chronic inflammatory disease. Treated volunteers had fewer of these cells in blood and inflamed skin. Pain subsided faster, but heat, redness and swelling did not materially change.
Laboratory experiments helped connect the observations. The molecule 12,13-EpOME limited the transition from classical monocytes into intermediate monocytes by reducing activity in p38 MAPK, a protein signaling pathway inside cells. A separate small experiment using a p38 inhibitor in older volunteers supported that connection.
This is more specific than showing that a drug simply switches off inflammation. It identifies a way to influence which immune cells emerge during the response. Pain resolution improved, while several other visible features followed much the same course.
Why aging researchers may care
Inflammaging is the persistent, low-level inflammation often associated with older age. It differs from the short-lived response to an injury, although some of the same immune machinery may be involved. Understanding how the body brings a temporary response under control could help researchers investigate why inflammatory activity sometimes persists.
The potential relevance is therefore mechanistic: a pathway that regulates immune-cell development could become a target for disease research. Demonstrating that such a target exists is an earlier step than showing that treating it improves an older person’s health.
Trials would need to establish benefits that patients can feel or that prevent tissue damage. A lower immune-cell count alone cannot answer whether a treatment reduces disability, prevents disease or extends healthy life.
The limitations and unanswered questions
The main experiments recruited healthy, nonsmoking men aged 18 to 50 and followed an acute skin response over 48 hours. They cannot establish effects in women, in chronically inflamed organs or during long-term treatment. The lack of randomization and placebo control also leaves room for bias, particularly in self-reported pain. Sample sizes were not set by a formal statistical power calculation.
Immune cells have useful roles as well as harmful ones. The paper linked reduced intermediate monocytes with fewer tissue CD4 T cells, immune cells involved in coordinating responses. Further work must examine infection defense, repair and immune balance, rather than assuming fewer inflammatory cells is always better.
No adverse events were reported in this study group, but that is not evidence of long-term safety. UCL identifies rheumatoid arthritis and cardiovascular disease as possible areas for future trials. Whether sEH inhibition improves either condition remains to be tested.
The Lifespan Brief assessment
This is promising human mechanism research with a defined experimental intervention and a plausible cellular explanation. It gives scientists a more precise question to test: can preserving selected lipid signals improve the resolution of harmful inflammation in patients? It supplies no evidence that human aging was slowed.
Sources
Bracken OV, Jalali P, et al. Epoxy-oxylipins direct monocyte fate in inflammatory resolution in humans. Nature Communications (2026). Open full text and methods.
UCL: Scientists discover natural ‘brake’ that could stop harmful inflammation, January 16, 2026. Study-design details above follow the original paper where the sources differ.
Feature image: original AI-generated conceptual illustration of inflammatory resolution, not a microscopy image.